Existing Anti-Seizure Drug Shows Promise Against Aggressive Childhood Brain Tumors

3h ago September 17, 2026 1 min read 📰 Medical Xpress

📋 Key Takeaway

Stanford Medicine research indicates that an existing anti-seizure drug can slow the growth of aggressive childhood brain tumors known as diffuse midline gliomas, which affect hundreds of children annually in the U.S. This finding is significant as it may lead to new treatment options for similar conditions in Iran, where healthcare advancements are crucial.

🔍 Quick Context Guide

💡 Bottom Line: The discovery of an existing drug's potential to treat aggressive childhood brain tumors could significantly impact treatment options for affected children in Iran and beyond.

👥 Key Players

Stanford Medicine MENTIONED

Research institution

"Stanford Medicine is a leading research institution that contributes to advancements in medical science, which can have implications for healthcare in Iran."

📰 What Happened

Research from Stanford Medicine has shown that an existing anti-seizure drug can slow the growth of aggressive childhood brain tumors known as diffuse midline gliomas. This discovery could lead to new treatment options for affected children.

Diffuse midline gliomas affect 300 to 400 children in the U.S. each year.
The five-year survival rate for these tumors is approximately 1%.

💡 Why It Matters

🇮🇷 For Iran: This finding could provide new hope for Iranian children suffering from similar aggressive cancers, where treatment options are often limited.

🌍 Regional: Improved cancer treatment could enhance healthcare standards in the region, potentially benefiting neighboring countries.

🌐 International: This research may encourage international collaboration in pediatric oncology and drug development.

📚 Background

Diffuse midline gliomas are a rare but deadly form of brain cancer in children, highlighting the urgent need for effective treatments. Existing therapies have limited success, making new research critical.

Childhood cancer treatment Oncology research advancements

📡 Source: NEUTRAL

📊 Confidence: 70%

The research is published by a reputable medical institution, suggesting a focus on scientific evidence rather than political bias.

An existing anti-seizure drug slows the growth of a devastating group of childhood cancers, new Stanford Medicine-led research has shown. The tumors, called diffuse midline gliomas, strike the brain and spinal cord. They affect 300 to 400 U.S. children per year and have a five-year survival rate of about 1%.